KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Amortization of Deferred Charges (2016 - 2025)

Historic Amortization of Deferred Charges for Ionis Pharmaceuticals (IONS) over the last 13 years, with Q3 2025 value amounting to $1.7 million.

  • Ionis Pharmaceuticals' Amortization of Deferred Charges fell 154.95% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.6 million, marking a year-over-year decrease of 98.8%. This contributed to the annual value of $6.7 million for FY2024, which is 568.72% up from last year.
  • Per Ionis Pharmaceuticals' latest filing, its Amortization of Deferred Charges stood at $1.7 million for Q3 2025, which was down 154.95% from $1.6 million recorded in Q2 2025.
  • In the past 5 years, Ionis Pharmaceuticals' Amortization of Deferred Charges ranged from a high of $1.7 million in Q3 2023 and a low of $860000.0 during Q1 2021
  • Over the past 5 years, Ionis Pharmaceuticals' median Amortization of Deferred Charges value was $1.5 million (recorded in 2023), while the average stood at $1.5 million.
  • In the last 5 years, Ionis Pharmaceuticals' Amortization of Deferred Charges skyrocketed by 6178.86% in 2021 and then tumbled by 330.22% in 2022.
  • Over the past 5 years, Ionis Pharmaceuticals' Amortization of Deferred Charges (Quarter) stood at $1.4 million in 2021, then fell by 2.48% to $1.3 million in 2022, then grew by 24.36% to $1.7 million in 2023, then increased by 0.6% to $1.7 million in 2024, then dropped by 1.31% to $1.7 million in 2025.
  • Its last three reported values are $1.7 million in Q3 2025, $1.6 million for Q2 2025, and $1.6 million during Q1 2025.